Multicentre observational study evaluating immediate and progressive switching from carbamazepine to oxcarbazepine in patients with epilepsy
- PMID: 17637215
Multicentre observational study evaluating immediate and progressive switching from carbamazepine to oxcarbazepine in patients with epilepsy
Abstract
This observational study was performed to identify the clinical reasons leading physicians to opt for immediate or progressive procedures when switching patients from carbamazepine to oxcarbazepine, and to evaluate the clinical feasibility of the two procedures in a general unselected patient population. Five hundred and twenty-seven patients (aged 14 years or older, treated with carbamazepine as monotherapy or in combination therapy) were recruited at 50 Italian centres and freely assigned to immediate (n=361) or progressive (n=166) switch procedures. Vital and clinical data (including seizure frequency) were comparable in the two groups at baseline. The proportion of patients with simple partial seizures only was significantly higher in the immediate group (immediate: 33.0% vs progressive: 23.5%, p=0.0275), whereas the proportion of patients on combination therapy was slightly higher in the progressive group (immediate: 47.1 vs progressive: 55.4%, p=0.0756). At the end of the switch period, overall treatment satisfaction was greater in the immediate switch group, both in patients (p<0.002) and physicians (p<0.0005). Physicians preferred the immediate over the progressive switch procedure. The only clinical features of patients found to relate to the physician?s choice of switch procedure were simple partial seizures only (favouring the immediate switch) and, possibly, combination therapy with other anti-epileptic drugs (favouring the progressive switch). "Overnight" switching from carbamazepine to oxcarbazepine also appears feasible in most patients on polytherapy.
Similar articles
-
Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy is equivalent to a progressive switch.Seizure. 2004 Jun;13(4):254-63. doi: 10.1016/j.seizure.2003.08.006. Seizure. 2004. PMID: 15121136 Clinical Trial.
-
Clinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy.Seizure. 2010 Jul;19(6):356-8. doi: 10.1016/j.seizure.2010.05.002. Epub 2010 Jun 9. Seizure. 2010. PMID: 20538492
-
Oxcarbazepine long-term treatment retention in patients switched over from carbamazepine.Neurol Sci. 2006 Jul;27(3):173-5. doi: 10.1007/s10072-006-0663-2. Neurol Sci. 2006. PMID: 16897629
-
What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?Epilepsy Behav. 2004 Oct;5(5):627-35. doi: 10.1016/j.yebeh.2004.07.004. Epilepsy Behav. 2004. PMID: 15380112 Review.
-
Long-term safety and tolerability of oxcarbazepine in children: a review of clinical experience.Epilepsy Behav. 2005 Nov;7(3):375-82. doi: 10.1016/j.yebeh.2005.07.017. Epub 2005 Sep 19. Epilepsy Behav. 2005. PMID: 16176888 Review.
Cited by
-
Oxcarbazepine for refractory epilepsy: systematic review of the literature.Sao Paulo Med J. 2009;127(3):150-9. doi: 10.1590/s1516-31802009000300008. Sao Paulo Med J. 2009. PMID: 19820875 Free PMC article.
-
Long-term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open-label extension study.Epilepsia. 2020 Oct;61(10):2129-2141. doi: 10.1111/epi.16666. Epub 2020 Sep 17. Epilepsia. 2020. PMID: 32944934 Free PMC article. Clinical Trial.